Foghorn Therapeutics Inc. (FHTX) vs Unicycive Therapeutics, Inc. (UNCY)
A side-by-side comparison of Foghorn Therapeutics Inc. and Unicycive Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FHTX
Foghorn Therapeutics Inc.
$1.97HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
UNCY
Unicycive Therapeutics, Inc.
$4.23HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — FHTX vs UNCY
growth of $100 · dividends reinvested · last 5yFHTX -79.6% (-27.2%/yr)UNCY -91.6% (-39.1%/yr)FHTX compounded faster over this window
FHTX UNCY
FHTX vs UNCY: by the numbers
- •FHTX is the larger company ($116M vs $113M market cap).
- •Both run net losses; UNCY's is the smaller (0.00% vs -175.78% net margin).
Metrics side by side
Valuation
| Metric | FHTX | UNCY |
|---|---|---|
| P/S ratio | 3.15 | N/A |
| P/B ratio | N/A | 2.12 |
Profitability
| Metric | FHTX | UNCY |
|---|---|---|
| Gross margin | 89.22% | 0.00% |
| Operating margin | -265.64% | 0.00% |
| Net margin | -175.78% | 0.00% |
| ROE | N/A | -66.12% |
| ROIC | -44.81% | -62.15% |
Growth (annualized)
| Metric | FHTX | UNCY |
|---|---|---|
| Revenue CAGR (5Y) | 105.83% | N/A |
| Total return CAGR (5Y) | -31.87% | -32.14% |
Frequently asked
- How have FHTX and UNCY total returns compared?
- Over the past 5 years, FHTX delivered -31.87% and UNCY delivered -32.14% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Foghorn Therapeutics ROEUnicycive Therapeutics ROEFoghorn Therapeutics operating marginUnicycive Therapeutics operating marginFoghorn Therapeutics revenue growthUnicycive Therapeutics revenue growthFoghorn Therapeutics free cash flowUnicycive Therapeutics free cash flow
Foghorn Therapeutics & Unicycive Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.